David J. Serisier

Effect of Long-term, Low-Dose Erythromycin on Pulmonary Exacerbations Among Patients With Non–Cystic Fibrosis Bronchiectasis

David J. Serisier, Megan Martin, Michael A. McGuckin et al. · JAMA · 2013 · 399 citations

Characterization of Bacterial Community Diversity in Cystic Fibrosis Lung Infections by Use of 16S Ribosomal DNA Terminal Restriction Fragment Length Polymorphism Profiling

Geraint B. Rogers, M. P. Carroll, David J. Serisier et al. · Journal of Clinical Microbiology · 2004 · 310 citations · Full text

Progressive Loss, Genetics, Klebsiella Pneumoniae +16

Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial

David J. Serisier, Diana Bilton, Anthony De Soyza et al. · Thorax · 2013 · 243 citations · Full text

A Novel Microbiota Stratification System Predicts Future Exacerbations in Bronchiectasis

Geraint B. Rogers, Nur Masirah M. Zain, Kenneth D. Bruce et al. · Annals of the American Thoracic Society · 2014 · 232 citations

The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial

Geraint B. Rogers, Kenneth D. Bruce, Megan Martin et al. · The Lancet Respiratory Medicine · 2014 · 226 citations

Respiratory Microbiota Composition, Non-cystic Fibrosis Bronchiectasis, Placebo-controlled Bless Trial +8